Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Emerging Pharmacotherapeutic Approaches for the Management of Sickle Cell Disease
source: Expert Opinion on Pharmacotherapy
year: 2019
authors: Torres L, Conran N
summary/abstract:Introduction:
Sickle cell disease (SCD) is an inherited disease with lifelong morbidity, whose complications include frequent acute painful vaso-occlusive episodes (VOEs) that often require hospitalization. The only pharmacotherapy currently in regular use for SCD management is hydroxyurea (hydroxycarbamide).
Areas Covered:
We review recent advances in pharmacotherapy for SCD and summarize promising synthetic agents that are in late-stage development (phase 3) for SCD.
Expert Opinion:
Emerging SCD therapies have been developed to target specific pathophysiological mechanisms of the disease, as either preventative or abortive approaches to VOEs. Continuous-use pharmacotherapeutics in late-phase development for VOE prevention include voxelotor (GBT440), which elevates hemoglobin oxygenation, and prasugrel, a platelet activation inhibitor. However, at least in the near future, it is probable that biological molecules will play a primary role in SCD preventative therapy; in combination with hydroxyurea, crizanlizumab, an anti-P-selectin monoclonal antibody, appears to reduce VOE frequency, while L-glutamine was the first substance licensed by the FDA for use in SCD in 20 years. Synthetic drugs, however, may represent key approaches for the management of individuals upon hospitalization for VOE, a major challenge for SCD. For example, rivipansel (GMI-1070), a pan-selectin inhibitor, has shown encouraging effects on hospitalization time and opioid use.
DOI: 10.1080/14656566.2018.1548610
read more
+myBinderRelated Content
-
A randomized controlled trial of home-based computerized working memory training for children with sickle cell disea...Objectives: To determine the effects of...
-
Sickle Cell Disease: Treatments – PAINWeekhttps://www.youtube.com/watch?v=llqCdRNK...
-
Determining Adherence to Quality Indicators in Sickle Cell Anemia Using Multiple Data SourcesINTRODUCTION: Advances in primary prophy...
-
FDA Approves Glutamine Powder for Sickle Cell DiseaseThe U.S. Food and Drug Administration ap...
-
SCDAA News Advisory: SCDAA Statement on Exa-cel Gene TherapyOn October 31, 2023, the Food and Drug A...
-
Stepping Up: Calvanay’s advicehttps://www.youtube.com/watch?v=_x9Dhrim...
-
Amanda M. Brandow, DO, MSDr. Brandow is a board certified pediatr...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.